Sign in
Taking peoplePhase 4

Semaglutide and wound closure time in people with diabetic foot ulcers

Tests whether semaglutide changes how fast diabetic foot wounds close in adults.

Key facts

Who runs it
Radboud universitair medisch centrum Stichting
Where
Netherlands1 site in 1 countryChoose a country to see its sites
Registry title
Healing Diabetic Foot Ulcers with Semaglutide
Status
Recruiting
Phase
Phase 4
People taking part
70 people, planned
Started
29 Jul 2026
Expected to end
1 Jan 2028
Type of study
Interventional
Record updated
19 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with type 2 diabetes who have an open foot wound (diabetic foot ulcer). It tests whether semaglutide helps the wound close faster.

Age
Over 18 years
Sex
All sexes
Disease stage
Type 2 diabetes with an active diabetic foot ulcer.
Earlier treatment
People cannot join if they now use, or used in the previous 6 months, a GLP-1RA or GLP-1/GIP co-agonist medicine.

Main reasons for not taking part

  • Allergy to the contents of semaglutide injections
  • Current pregnancy
  • Past pancreatitis (inflamed pancreas) caused by a GLP-1RA medicine
  • End-stage kidney disease (estimated-GFR <15 mL/min/m2) or on kidney replacement treatment such as dialysis
  • Current anti-inflammatory treatment such as prednisolone, or life expectancy <3 months

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Have type 2 diabetes mellitus (T2DM)
  • Presence of an active diabetic foot ulcer
  • Age >18 years
  • Be proficient in either Dutch or English

Who cannot take part

  • Those with current use or who used a GLP-1RA or GLP-1/GIP co-agonist in the previous 6 months
  • Previous pancreatitis attributed to use of GLP-1RA
  • Current use of anti-inflammatory therapy, e.g. prednisolone
  • Any contra-indication for semaglutide as outlined in the EPAR (which only consists of allergy to the contents of semaglutide injections)
  • End-stage renal disease (defined as estimated-GFR <15 mL/min/m2 or the use of renal replacement therapy)
  • Current pregnancy
  • Life expectancy <3 months

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To demonstrate the effect of semaglutide on the time to wound closure in patients with a diabetic foot wound.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Healing Diabetic Foot Ulcers with Semaglutide
Plain-language title
Semaglutide and wound closure time in people with diabetic foot ulcersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
19 May 2026